Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 39.38.
Forward PE Ratio (39.38) = Close Price ($351.37) / Consensus Forward EPS ($8.94)
FORWARD PE RATIO
39.38
SECTOR MEDIAN · HEALTHCARE
20.09
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
+96.02%
vs the sector median at left
West Pharmaceutical Services, Inc.
Market Cap
$24.73B
Forward PE Ratio
39.38
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.73B | 39.38 |
| Incyte Corporation (INCY)vs › | $24.54B | 29.06 |
| Moderna, Inc. (MRNA)vs › | $24.03B | N/A |
| BioNTech SE (BNTX)vs › | $23.31B | N/A |
| Quest Diagnostics Incorporated (DGX)vs › | $26.21B | 21.23 |
| STERIS plc (STE)vs › | $23.22B | 23.43 |
| Labcorp Holdings Inc. (LH)vs › | $26.44B | 17.60 |
| United Therapeutics Corporation (UTHR)vs › | $21.88B | 20.09 |
| Mettler-Toledo International Inc. (MTD)vs › | $29.04B | 30.31 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.60B | 32.08 |
Trailing P/E
45.0
reported TTM EPS
Forward P/E
39.4
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.94 implies +14.3% EPS growth vs the reported trailing $7.82.
At today's $351.37 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.94 | $8.56 – $9.06 | 10 | 39.3x |
| 2027-12-31 | $9.95 | $9.32 – $10.18 | 10 | 35.3x |
| 2028-12-31 | $11.29 | $10.28 – $12.43 | 5 | 31.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
